Retina (Philadelphia, Pa.)
via Europe PMC
EVALUATING THE EFFICACY AND SAFETY OF TOPICAL DIFLUPREDNATE IN PATIENTS WITH CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Yadav P, Shakha, Mishra S, +7 more, Vohra R.
AI summary — for doctors, generated from the abstract only
In a small pilot RCT, topical difluprednate resolved subretinal fluid in chronic CSC more often than oral eplerenone or observation.
What was studied
Open-label pilot randomized trial of 53 adults (90.6% male) with chronic CSC randomized to topical difluprednate 0.05%, oral eplerenone or observation, followed for 3 months.
Key findings
- Complete subretinal fluid resolution in 90% (difluprednate), 45% (eplerenone) and 23% (observation)
- Difluprednate also improved choroidal thickness and retinal sensitivity
- Safety profile described as manageable
Clinical relevance
Offers a possible topical option for chronic CSC, though corticosteroids can worsen CSC and need caution.
Who should care
Limitations
Pilot, open-label, short 3-month follow-up and small groups; steroid-related risks and recurrence not fully addressed in the abstract.
Wait for larger, longer trials before using topical difluprednate for CSC outside research.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Purpose
To evaluate the efficacy and safety of topical difluprednate ophthalmic emulsion 0.05% in chronic central serous chorioretinopathy (cCSCR) and compare its outcomes with oral eplerenone and observation.
Methods
This pilot open-label randomized controlled trial included patients with cCSCR of ≥3 months' duration or relapsing cases with subfoveal or juxtafoveal leakage on angiography. After baseline assessment, patients were randomized into three groups: topical difluprednate, oral eplerenone, or observation. All participants were followed monthly for 3 months. Changes in best-corrected visual acuity, optical coherence tomography parameters, retinal sensitivity, and adverse events were documented.
Results
A total of 53 adults (mean age 42.6 ± 9.5 years; 90.6% male) were enrolled. Complete resolution of subretinal fluid occurred in 90% (n = 18) of the patients in the difluprednate group, 45% (n = 9) in eplerenone group, and 23% (n = 3) patients in the control arm ( P < 0.001). The difluprednate group showed significantly greater reductions in subfoveal choroidal thickness and improvements in 3-mm microperimetry thresholds compared with the observation group ( P = 0.012 and P = 0.022, respectively). It also demonstrated the largest decrease in central macular thickness, although this was not statistically significant ( P = 0.19). Ocular hypertension developed in 30% of difluprednate-treated eyes and was controlled with topical antiglaucoma medication.
Conclusion
Topical difluprednate produced superior anatomical and functional improvements in subretinal fluid resolution, subfoveal choroidal thickness reduction, and retinal sensitivity within 3-mm when compared with oral eplerenone and observation. Thus, with a manageable safety profile, it may serve as an effective therapeutic option for cCSCR.
DOI
10.1097/iae.0000000000004943
PMID
42531436
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed